Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has reiterated a Buy rating for Sonnet BioTherapeutics (NASDAQ:SONN) and maintained a price target of $30.
August 23, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Sonnet BioTherapeutics, maintaining a $30 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $30 price target by Chardan Capital suggests a positive outlook for Sonnet BioTherapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100